News & Research — MesoWatch

93 Clinical Trials Are Recruiting Mesothelioma Patients Right Now. Here's What's Being Tested.

news Jan 28, 2026

93 Clinical Trials Are Recruiting Mesothelioma Patients Right Now. Here's What's Being Tested.

93 mesothelioma trials recruiting now. Immunotherapy leads with 32 trials, CAR-T emerges with 5. Complete 2026 data by state, phase, and treatment type.

MesoWatch Editorial

Latest News

The Asbestos Cover-Up: What the Industry Knew in 1930

The Asbestos Cover-Up: What the Industry Knew in 1930

Your Mechanic May Be Breathing Asbestos Right Now

Your Mechanic May Be Breathing Asbestos Right Now

3,000 Americans Die From Mesothelioma Every Year. Here's Who They Are.

3,000 Americans Die From Mesothelioma Every Year. Here's Who They Are.

The Hidden Danger in Your Ceiling

The Hidden Danger in Your Ceiling

Advocates Sue for East Wing Asbestos Records

Advocates Sue for East Wing Asbestos Records

New Review Maps BAP1 Loss in Mesothelioma

New Review Maps BAP1 Loss in Mesothelioma

UK Recalls Children's Play Sand After Asbestos Found

UK Recalls Children's Play Sand After Asbestos Found

UK, EU Split on Talc Cancer Classification

UK, EU Split on Talc Cancer Classification

Mesothelioma Lawsuit: $42.6M J&J Verdict — MesoWatch

Mesothelioma Lawsuit: $42.6M J&J Verdict — MesoWatch

Montana Windstorm Scatters School Asbestos

Montana Windstorm Scatters School Asbestos

Cell Therapy Shrinks Tumors in 63%

Cell Therapy Shrinks Tumors in 63%

Cassiar: The Town That Asbestos Built

Cassiar: The Town That Asbestos Built

Vi-Jon Talc Mesothelioma Trial in California

Vi-Jon Talc Mesothelioma Trial in California

Cold Lake School Closes After Asbestos Found

Cold Lake School Closes After Asbestos Found

Malaysia Asbestos Ban Push Intensifies

Malaysia Asbestos Ban Push Intensifies

J&J Talc Verdicts Top $2.5B in 2025

J&J Talc Verdicts Top $2.5B in 2025

Mesothelioma Treatment Advances: 2025

Mesothelioma Treatment Advances: 2025

Record $1.56B Verdict Against J&J in Talc

Record $1.56B Verdict Against J&J in Talc

$65.5M J&J Talc Verdict in Minnesota

$65.5M J&J Talc Verdict in Minnesota

Talc Lawsuit: $40M J&J Verdict, Ovarian Cancer — MesoWatch

Talc Lawsuit: $40M J&J Verdict, Ovarian Cancer — MesoWatch

Drug Combo Achieves 60% Response Rate

Drug Combo Achieves 60% Response Rate

FDA Withdraws Talc Asbestos Testing Rule

FDA Withdraws Talc Asbestos Testing Rule

One Drug Halted, Another Advances

One Drug Halted, Another Advances

Asbestos in Children's Art Sand: Australia

Asbestos in Children's Art Sand: Australia

Judge Allows Experts in 67,500 Talc Cases

Judge Allows Experts in 67,500 Talc Cases

Japan Banned Asbestos in 2006, Cases Rise

Japan Banned Asbestos in 2006, Cases Rise

Mesothelioma Lawsuit: $20M J&J Florida Verdict — MesoWatch

Mesothelioma Lawsuit: $20M J&J Florida Verdict — MesoWatch

Minot AFB Missile Crews Face Asbestos Risk

Minot AFB Missile Crews Face Asbestos Risk

Mesothelioma Survival: 18-Year Survivor's Story — MesoWatch

Mesothelioma Survival: 18-Year Survivor's Story — MesoWatch

$966M Verdict: J&J Liable for Talc Death

$966M Verdict: J&J Liable for Talc Death

Mesothelioma Awareness Day: September 26

Mesothelioma Awareness Day: September 26

Mesothelioma Treatment: Hopkins Immunotherapy Trial — MesoWatch

Mesothelioma Treatment: Hopkins Immunotherapy Trial — MesoWatch

VT3989 Doubles Time Without Progression

VT3989 Doubles Time Without Progression

Immunotherapy Trial: Phase 2 Study for Mesothelioma — MesoWatch

clinical-trials

Immunotherapy Trial: Phase 2 Study for Mesothelioma — MesoWatch

Hopkins: Pre-Surgery Immunotherapy Success

Hopkins: Pre-Surgery Immunotherapy Success

Trial Tests Immunotherapy Before Surgery

Trial Tests Immunotherapy Before Surgery

IMPALA Trial: Light Therapy for Mesothelioma

IMPALA Trial: Light Therapy for Mesothelioma

Paramount Studios Faces Asbestos Suits

Paramount Studios Faces Asbestos Suits

Nivolumab + Ipilimumab Trial for Pleural Mesothelioma — MesoWatch

clinical-trials

Nivolumab + Ipilimumab Trial for Pleural Mesothelioma — MesoWatch

CAR-T Trial: Phase 1 Study for Mesothelioma — MesoWatch

clinical-trials

CAR-T Trial: Phase 1 Study for Mesothelioma — MesoWatch

Asbestos Disclosure Bill H.R.4247

Asbestos Disclosure Bill H.R.4247

Libby, Montana: America's Deadliest Town

Libby, Montana: America's Deadliest Town

Dual-Target Immunotherapy Shows 52% Response

Dual-Target Immunotherapy Shows 52% Response

UK Commits £1.2B for Asbestos Removal

UK Commits £1.2B for Asbestos Removal

UK Has World's Highest Meso Rates

UK Has World's Highest Meso Rates

Canada Banned Asbestos, Cases Still Rise

Canada Banned Asbestos, Cases Still Rise

FDA Approves Opdivo Qvantig for Mesothelioma

FDA Approves Opdivo Qvantig for Mesothelioma

Utah Windstorm Spreads Mine Asbestos

Utah Windstorm Spreads Mine Asbestos

Nivolumab + Ipilimumab Phase 2 Trial for Mesothelioma — MesoWatch

clinical-trials

Nivolumab + Ipilimumab Phase 2 Trial for Mesothelioma — MesoWatch

KEYNOTE-483: Keytruda Combo Approved

KEYNOTE-483: Keytruda Combo Approved

Pembrolizumab Trial: Phase 1 Study for Mesothelioma — MesoWatch

clinical-trials

Pembrolizumab Trial: Phase 1 Study for Mesothelioma — MesoWatch

9/11 Mesothelioma Crisis Still Unfolding

9/11 Mesothelioma Crisis Still Unfolding

Nivolumab + Ipilimumab Phase 1 Trial for Mesothelioma — MesoWatch

clinical-trials

Nivolumab + Ipilimumab Phase 1 Trial for Mesothelioma — MesoWatch

DENIM Trial: Vaccine Did Not Extend Survival

DENIM Trial: Vaccine Did Not Extend Survival

WHO Classifies Talc as Probable Carcinogen

WHO Classifies Talc as Probable Carcinogen

Immunotherapy Trial: Phase 1 Study for Mesothelioma — MesoWatch

clinical-trials

Immunotherapy Trial: Phase 1 Study for Mesothelioma — MesoWatch

Immunotherapy Trial: Phase 2 Study for Mesothelioma — MesoWatch

clinical-trials

Immunotherapy Trial: Phase 2 Study for Mesothelioma — MesoWatch

CAR-T Trial: Phase 1 Study for Pleural Mesothelioma — MesoWatch

clinical-trials

CAR-T Trial: Phase 1 Study for Pleural Mesothelioma — MesoWatch

MARS 2: Chemo Outperformed Surgery

MARS 2: Chemo Outperformed Surgery

CAR-T Trial: Phase 1 Study for Mesothelioma — MesoWatch

clinical-trials

CAR-T Trial: Phase 1 Study for Mesothelioma — MesoWatch

EPA Bans Chrysotile: First U.S. Asbestos Ban

EPA Bans Chrysotile: First U.S. Asbestos Ban

Pembrolizumab Phase 2 Trial for Pleural Mesothelioma — MesoWatch

clinical-trials

Pembrolizumab Phase 2 Trial for Pleural Mesothelioma — MesoWatch

CAR-T Trial: Phase 1 Study for Mesothelioma — MesoWatch

clinical-trials

CAR-T Trial: Phase 1 Study for Mesothelioma — MesoWatch

ATOMIC-Meso: Quadrupled 3-Year Survival

ATOMIC-Meso: Quadrupled 3-Year Survival

CONFIRM Trial: Nivolumab Extends Survival

CONFIRM Trial: Nivolumab Extends Survival

2023 Mesothelioma Verdicts: $40M+ Awards

2023 Mesothelioma Verdicts: $40M+ Awards

Nivolumab + Ipilimumab Trial for Pleural Mesothelioma — MesoWatch

clinical-trials

Nivolumab + Ipilimumab Trial for Pleural Mesothelioma — MesoWatch

Nivolumab + Ipilimumab Trial: Study for Mesothelioma — MesoWatch

clinical-trials

Nivolumab + Ipilimumab Trial: Study for Mesothelioma — MesoWatch

HIPEC Trial: Phase 2 Study for Peritoneal Mesothelioma — MesoWatch

clinical-trials

HIPEC Trial: Phase 2 Study for Peritoneal Mesothelioma — MesoWatch

Court Rejects J&J's 2nd Talc Bankruptcy

Court Rejects J&J's 2nd Talc Bankruptcy

Atezolizumab Trial: Phase 1 Study for Mesothelioma — MesoWatch

clinical-trials

Atezolizumab Trial: Phase 1 Study for Mesothelioma — MesoWatch

SynKIR-110 CAR-T Gets FDA Fast-Track

SynKIR-110 CAR-T Gets FDA Fast-Track

Pembrolizumab Trial: Phase 1 Study for Mesothelioma — MesoWatch

clinical-trials

Pembrolizumab Trial: Phase 1 Study for Mesothelioma — MesoWatch

J&J Discontinues Talc Baby Powder

J&J Discontinues Talc Baby Powder

Immunotherapy Trial: Phase 2 Study for Mesothelioma — MesoWatch

clinical-trials

Immunotherapy Trial: Phase 2 Study for Mesothelioma — MesoWatch

Atezolizumab Phase 1 Trial for Pleural Mesothelioma — MesoWatch

clinical-trials

Atezolizumab Phase 1 Trial for Pleural Mesothelioma — MesoWatch

Pembrolizumab Trial: Phase 1 Study for Mesothelioma — MesoWatch

clinical-trials

Pembrolizumab Trial: Phase 1 Study for Mesothelioma — MesoWatch

Nivolumab + Ipilimumab Trial for Pleural Mesothelioma — MesoWatch

clinical-trials

Nivolumab + Ipilimumab Trial for Pleural Mesothelioma — MesoWatch

EPA Proposes Chrysotile Asbestos Ban

EPA Proposes Chrysotile Asbestos Ban

HIPEC Trial: Phase 2 Study for Peritoneal Mesothelioma — MesoWatch

clinical-trials

HIPEC Trial: Phase 2 Study for Peritoneal Mesothelioma — MesoWatch

Atezolizumab Phase 3 Trial for Pleural Mesothelioma — MesoWatch

clinical-trials

Atezolizumab Phase 3 Trial for Pleural Mesothelioma — MesoWatch

CAR-T Trial: Study for Mesothelioma — MesoWatch

clinical-trials

CAR-T Trial: Study for Mesothelioma — MesoWatch

HIPEC Trial: Phase 1 Study for Peritoneal Mesothelioma — MesoWatch

clinical-trials

HIPEC Trial: Phase 1 Study for Peritoneal Mesothelioma — MesoWatch

J&J Creates LTL to Shield Talc Liability

J&J Creates LTL to Shield Talc Liability

J&J's Texas Two-Step: 3 Failed Attempts

J&J's Texas Two-Step: 3 Failed Attempts

Pembrolizumab Trial: Phase 1 Study for Mesothelioma — MesoWatch

clinical-trials

Pembrolizumab Trial: Phase 1 Study for Mesothelioma — MesoWatch

Pembrolizumab Trial: Phase 1 Study for Mesothelioma — MesoWatch

clinical-trials

Pembrolizumab Trial: Phase 1 Study for Mesothelioma — MesoWatch

Nivolumab + Ipilimumab Phase 1 Trial for Mesothelioma — MesoWatch

clinical-trials

Nivolumab + Ipilimumab Phase 1 Trial for Mesothelioma — MesoWatch

FDA OKs Opdivo+Yervoy for Mesothelioma

FDA OKs Opdivo+Yervoy for Mesothelioma

CheckMate-743: Immunotherapy Beats Chemo

CheckMate-743: Immunotherapy Beats Chemo

Jury Awards $750M to 4 Meso Patients

Jury Awards $750M to 4 Meso Patients

Immunotherapy Trial: Phase 2 Study for Mesothelioma — MesoWatch

clinical-trials

Immunotherapy Trial: Phase 2 Study for Mesothelioma — MesoWatch

FDA Finds Asbestos in J&J Baby Powder

FDA Finds Asbestos in J&J Baby Powder

FDA Approves Optune Lua for Mesothelioma

FDA Approves Optune Lua for Mesothelioma

FDA Finds Asbestos in Claire's Makeup

FDA Finds Asbestos in Claire's Makeup

St. Louis Jury Awards $4.69B in Talc Case

St. Louis Jury Awards $4.69B in Talc Case

Pembrolizumab Trial: Phase 1 Study for Mesothelioma — MesoWatch

clinical-trials

Pembrolizumab Trial: Phase 1 Study for Mesothelioma — MesoWatch

Brazil Supreme Court Bans Asbestos

Brazil Supreme Court Bans Asbestos

Lautenberg Act: Path to Asbestos Ban

Lautenberg Act: Path to Asbestos Ban

Zadroga Act: Permanent Care for 9/11 Responders

Zadroga Act: Permanent Care for 9/11 Responders

Featured Coverage

In-depth reporting, data analysis, and investigations

Talcum Powder Crisis By the Numbers

Talcum Powder Crisis By the Numbers

The talc crisis by the numbers: 90,000+ lawsuits, $10B+ in verdicts, and decades of corporate knowledge. The data tells the story.